List of Excipients in Branded Drug PONVORY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Vanda Pharmaceuticals Inc	PONVORY	ponesimod	43068-620	CELLULOSE, MICROCRYSTALLINE	2029-11-16
Vanda Pharmaceuticals Inc	PONVORY	ponesimod	43068-620	CROSCARMELLOSE SODIUM	2029-11-16
Vanda Pharmaceuticals Inc	PONVORY	ponesimod	43068-620	FERRIC OXIDE YELLOW	2029-11-16
Vanda Pharmaceuticals Inc	PONVORY	ponesimod	43068-620	HYPROMELLOSE 2910	2029-11-16
Vanda Pharmaceuticals Inc	PONVORY	ponesimod	43068-620	LACTOSE MONOHYDRATE	2029-11-16
Vanda Pharmaceuticals Inc	PONVORY	ponesimod	43068-620	MAGNESIUM STEARATE	2029-11-16
Vanda Pharmaceuticals Inc	PONVORY	ponesimod	43068-620	POLYETHYLENE GLYCOL	2029-11-16

PONVORY Excipient Strategy and Commercial Opportunities

Last updated: September 23, 2026

PONVORY (ponesimod) is an oral sphingosine-1-phosphate receptor 1 modulator approved by the FDA for adults with relapsing forms of multiple sclerosis. Its formulation is commercially straightforward: immediate-release, film-coated tablets across seven strengths, with a 14-day dose-escalation regimen followed by a 20 mg maintenance dose. The main excipient opportunities are lactose-free reformulation, color-free presentation, improved low-dose content uniformity, and differentiated starter-pack manufacturing.

The strongest commercial opportunity is an excipient and packaging platform that supports consistent manufacture of the 2 mg to 20 mg strength range while reducing dependence on colorants, minimizing tablet-size differences, and improving patient adherence during titration.

What is the PONVORY formulation and which excipients does it contain?

PONVORY tablets use a conventional immediate-release tablet core and a film coating. The U.S. prescribing information identifies the following inactive ingredients:

Formulation component	Excipient or material	Primary function
Tablet core	Lactose monohydrate	Diluent and carrier
Tablet core	Microcrystalline cellulose	Diluent, compression aid, dry binder
Tablet core	Croscarmellose sodium	Superdisintegrant
Tablet core	Magnesium stearate	Lubricant
Film coating	Polyvinyl alcohol	Film former
Film coating	Titanium dioxide	Opacifier and whitening agent
Film coating	Talc	Anti-tacking and coating aid
Film coating	Iron oxides	Tablet-strength color differentiation

PONVORY is supplied as 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, and 10 mg tablets in the starter pack, followed by 20 mg maintenance tablets. The tablet colors and markings distinguish dose strengths and support the titration schedule. The 14-day starter pack contains one tablet for each titration day, while the maintenance presentation is supplied separately.[1]

The product does not use a modified-release polymer, lipid carrier, enteric coating, osmotic system, or biologic stabilizer. Its excipient strategy is therefore centered on manufacturability, disintegration, dose uniformity, coating performance, and product identification rather than controlled drug release.

How does the PONVORY dose-escalation regimen affect excipient strategy?

The starter pack creates a more demanding manufacturing and packaging profile than a single-strength maintenance product.

Ponesimod treatment begins at 2 mg and increases daily over 14 days before reaching 20 mg. Each strength must meet content-uniformity, dissolution, stability, and mechanical specifications. The lowest strengths are particularly important because a 2 mg tablet contains a relatively small amount of active pharmaceutical ingredient compared with the excipient mass.

Key formulation risks by dose strength

Risk	Most affected presentation	Commercial implication
Content uniformity	2 mg to 5 mg tablets	Requires robust powder blending and segregation control
Weight variation	Low-dose tablets	May affect dose accuracy and regulatory comparability
Tablet friability	Small starter-pack tablets	Can create packaging dust and breakage
Disintegration variability	All strengths	Directly affects immediate-release performance
Coating color variation	Starter-pack strengths	Can increase batch rejection and visual inspection cost
Packaging complexity	14-day starter pack	Requires multi-cavity blister or calendar-pack capability
Patient confusion	Entire titration sequence	Requires high-contrast color and printed dose identification

An excipient platform that improves powder flow and minimizes segregation has greater value than a simple low-cost diluent substitution. The most commercially relevant performance metrics are blend uniformity, tablet tensile strength, ejection force, disintegration time, and color consistency.

What excipient substitutions could create commercial opportunities for PONVORY?

Lactose-free formulation

Lactose monohydrate is the most obvious substitution target. A lactose-free version could use mannitol, anhydrous dibasic calcium phosphate, spray-dried sucrose, or a co-processed microcrystalline cellulose-based excipient.

Potential benefits include:

• Reduced reliance on lactose supply chains
• Positioning for patients with lactose intolerance
• Compatibility with manufacturers seeking plant-based or non-animal-derived excipient declarations
• Potentially improved moisture control with selected grades
• A differentiated product for markets where lactose labeling is commercially sensitive

The regulatory and commercial benefit would be limited if the current product contains only a small amount of lactose and does not generate clinically relevant intolerance. A lactose-free version would need a defined patient or market proposition, such as a regional procurement requirement, a private-label opportunity, or a broader “clean-label” portfolio strategy.

Co-processed direct-compression excipients

A co-processed microcrystalline cellulose and mannitol system could replace the separate lactose and microcrystalline cellulose components. Such systems can improve flow, compactibility, and tablet weight control.

For PONVORY, the principal value would be manufacturing simplification across nine dose strengths. A common excipient platform could support:

• Similar compression behavior across strengths
• Lower sensitivity to active concentration changes
• Better tablet hardness at small tablet weights
• Reduced lubricant sensitivity
• Lower risk of segregation during high-speed compression

The principal development issue is dissolution equivalence. Changes in porosity, water uptake, and disintegration behavior could alter the release profile even though PONVORY is an immediate-release product.

Low-moisture or moisture-robust excipients

Lactose, croscarmellose sodium, and film-coating systems can respond differently to humidity. A moisture-robust excipient system could use low-moisture grades of microcrystalline cellulose, mannitol, or dibasic calcium phosphate.

This opportunity is strongest in markets with:

• High humidity
• Long distribution routes
• Limited temperature control
• Blister packaging rather than bottles
• High seasonal exposure during transport

A formulation that reduces moisture uptake could lower dependence on high-barrier packaging. That would be commercially valuable, but the excipient change would need to be evaluated with the blister material, desiccant strategy, tablet hardness, and long-term stability program.

Color-free and iron-oxide-reduced presentations

The current multi-strength presentation uses color differentiation. A color-free or reduced-color design could respond to procurement requirements concerning titanium dioxide or synthetic pigments.

A practical alternative is to retain a white or off-white film coat and rely on:

• Dose-specific debossing
• Large printed strength numbers
• Distinct blister positions
• Titration-day labeling
• Barcode or near-field identification
• Shape or score differentiation where feasible

Removing colorants creates a human-factors risk. A 14-day escalation pack depends on rapid visual recognition. Any color-free strategy would require human-factors validation and strong packaging controls.

What formulations are protected by PONVORY-related intellectual property?

PONVORY’s core intellectual-property position is centered on ponesimod, pharmaceutical compositions, therapeutic use, and manufacturing technology. A conventional excipient combination generally provides weaker standalone protection than a novel delivery system.

Relative strength of formulation claim types

Claim category	Typical strength	Relevance to PONVORY
Ponesimod composition of matter	High	Protects the active compound
Therapeutic-use claims	Medium to high	Relevant to multiple sclerosis treatment
Solid-form or salt claims	Medium to high	Depends on the selected form
Specific immediate-release tablet composition	Medium	Can protect excipient ranges and performance
Coating-color claims	Low to medium	Usually easy to design around
Starter-pack configuration	Medium	May protect packaging and titration presentation
Manufacturing process	Medium to high	Stronger when linked to a critical quality attribute
Generic lactose-free reformulation	Low unless technically differentiated	Requires a credible inventive step

The commercial value of an excipient patent increases when the excipient produces an unexpected technical effect. Examples include improved low-dose content uniformity, a narrow dissolution profile across all strengths, reduced degradation, or a meaningful reduction in tablet size.

A claim covering only “ponesimod, lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate” would face significant obviousness and design-around pressure if similar immediate-release formulations are publicly known. A process claim tied to validated blend segregation control or a specific dissolution and stability profile would be more defensible.

When does PONVORY lose exclusivity?

PONVORY received FDA approval on March 18, 2021. FDA granted the product five years of new chemical entity exclusivity, which generally runs until March 18, 2026. An ANDA containing a Paragraph IV certification could be submitted before that date, but FDA approval would ordinarily be blocked until the statutory exclusivity period expires unless the exclusivity is otherwise affected.[2]

The relevant U.S. exclusivity framework is:

Event	Date or status
FDA approval	March 18, 2021
Five-year NCE exclusivity	Generally through March 18, 2026
Maintenance dose	20 mg
Dosage form	Immediate-release oral tablet
Regulatory pathway for generics	ANDA
Biosimilar pathway	Not applicable
Pediatric exclusivity	No separate extension identified in the FDA approval materials reviewed
Patent-based launch date	Depends on Orange Book-listed patents, litigation, and settlements

Ponesimod is a small molecule, not a biologic. Biosimilar approval is therefore not relevant. Future competition would enter through abbreviated new drug applications, not through the biosimilar pathway.

What is the Orange Book status of PONVORY?

PONVORY’s Orange Book position should be evaluated separately from statutory exclusivity. The Orange Book can list patents covering the active ingredient, pharmaceutical composition, method of use, or other approved product attributes. A patent listing does not itself establish that every claim will survive litigation or block every generic launch.

The commercially important questions are:

1. Which patents are listed against the specific PONVORY strengths and dosage form?
2. What are the listed patent expiration dates?
3. Do the listings cover the active compound, a formulation, a method of treatment, or a manufacturing process?
4. Has the NDA holder submitted a timely patent-listing update?
5. Have generic applicants filed Paragraph IV certifications?
6. Has litigation triggered a 30-month stay?
7. Does any settlement provide an authorized-generic or license-entry date?

Publicly available FDA materials identify PONVORY as a small-molecule prescription product. No biosimilar litigation framework applies. The principal competition risk is generic ponesimod after NCE exclusivity and any enforceable patent barriers expire.[2]

Because excipients are usually not listed as independent Orange Book protections unless they are part of a qualifying patent claim tied to the approved product, an excipient innovation may have limited value as an Orange Book blocker. Its greater value may arise through manufacturing know-how, regulatory differentiation, supply agreements, or a separate patent family.

Which companies could challenge PONVORY?

The likely challengers are established generic companies with experience in low-dose immediate-release tablets, multi-strength portfolios, and complex packaging. Potential participants in a ponesimod generic market would include companies with:

• S1P-modulator or multiple-sclerosis portfolios
• High-volume solid-dose manufacturing
• ANDA litigation capability
• Multi-strength tablet compression capacity
• Calendar-blister packaging operations
• Access to ponesimod active pharmaceutical ingredient

The most credible generic strategy would likely use the same broad dosage form while varying the inactive ingredients within FDA-acceptable limits. A generic applicant may seek to avoid the reference formulation’s color system, use a different diluent, or develop a different coating while preserving immediate-release performance.

What Paragraph IV challenges and litigation risks exist for PONVORY?

A Paragraph IV challenge would be commercially important because it could accelerate generic entry before patent expiration. The likely targets would be:

• Active-ingredient or compound patents
• Pharmaceutical-composition patents
• Method-of-use patents for relapsing multiple sclerosis
• Solid-form or polymorph patents
• Manufacturing patents that a generic applicant may need to practice

An excipient patent is less likely to be the main litigation target unless it covers an essential commercial formulation. Generic applicants normally have several routes to design around routine excipient combinations.

Potential litigation outcomes include:

Outcome	Commercial effect
Patent upheld	Delays generic entry until patent expiry
Patent invalidated	Accelerates entry
Settlement with licensed entry	Establishes a negotiated launch date
Authorized generic launch	Reduces the innovator’s exposure to third-party generic erosion
Narrow claim construction	Allows a non-infringing generic formulation
30-month stay	Delays FDA approval during litigation, subject to statutory limits

No biosimilar interchangeability or reference-product exclusivity issues apply because PONVORY is not a biologic.

How strong is the PONVORY patent estate for an excipient investor?

The estate is likely stronger around ponesimod and its clinical use than around conventional excipients. An excipient investor should rank opportunities as follows:

Opportunity	Patent strength	Commercial attractiveness
Novel ponesimod solid form	High if technically supported	High
Stability-enhancing formulation	Medium to high	High
Low-dose uniformity process	Medium	Medium to high
Co-processed excipient system	Medium	Medium
Lactose-free substitution alone	Low	Medium
Color substitution alone	Low	Low to medium
Starter-pack blister architecture	Medium	Medium
Proprietary coating process	Medium	Medium
Routine lactose/MCC/croscarmellose blend	Low	Low

The strongest investable program would combine a formulation claim with a measurable manufacturing or stability benefit. A formulation that reduces tablet weight, improves low-strength uniformity, or supports a smaller starter pack could create value through both intellectual property and cost reduction.

What regulatory pathway applies to a PONVORY excipient reformulation?

A reformulated PONVORY product would generally require a regulatory pathway determined by the sponsor’s relationship to the reference product and the extent of the change.

Innovator reformulation

The NDA holder could pursue a supplemental NDA if the change remains within the approved product framework. The supplement would typically require data on:

• Comparative dissolution
• Stability
• Content uniformity
• Tablet hardness and friability
• Manufacturing process validation
• Extractables and leachables, if packaging changes
• Updated inactive-ingredient justification
• Labeling or appearance changes
• Human-factors assessment for the starter pack

A major formulation change may require pharmacokinetic bridging or other clinical support, depending on its effect on exposure and the regulatory authority’s assessment.

Generic reformulation

A generic applicant would use an ANDA and demonstrate bioequivalence to the reference-listed drug. The applicant could use different inactive ingredients if the product meets applicable safety, quality, dissolution, and bioequivalence requirements.

The risk is greatest for the lowest strengths and the starter-pack sequence. A generic product that matches the 20 mg maintenance tablet but performs poorly at 2 mg or 3 mg would not provide a complete commercial substitute.

How does PONVORY compare with other multiple-sclerosis oral drugs?

PONVORY competes with oral disease-modifying therapies that have different formulation and exclusivity profiles.

Product	Active ingredient	Dosage form	Excipient opportunity
PONVORY	Ponesimod	Immediate-release tablets	Low-dose uniformity, lactose-free platform, starter pack
Gilenya	Fingolimod	Capsules	Capsule shell, low-dose fill, solid-state control
Mayzent	Siponimod	Tablets	Dose titration, polymorph and formulation control
Zeposia	Ozanimod	Capsules	Capsule composition, titration packaging
Aubagio	Teriflunomide	Tablets	Film coating, tablet size, generic manufacturing
Tecfidera	Dimethyl fumarate	Delayed-release capsules	Enteric coating and gastrointestinal tolerability
Kesimpta	Ofatumumab	Injection	Biologic formulation and device technology

PONVORY’s immediate-release tablet is technically less complex than delayed-release dimethyl fumarate or injectable ofatumumab. Its commercial differentiation therefore depends more on dose titration, adherence, packaging, and supply reliability.

What manufacturing and supply-chain barriers affect PONVORY excipient opportunities?

The main barriers are not unusual chemistry. They are scale-up and consistency across multiple strengths.

Critical manufacturing controls include:

• Active-to-excipient segregation during blending
• Lubrication time and magnesium stearate distribution
• Compression-force control
• Tablet weight accuracy at low doses
• Coating weight gain and color uniformity
• Blister-machine speed and pocket accuracy
• Stability under high humidity
• Visual inspection of nine starter-pack strengths
• Serialization and pack-level traceability

Excipient suppliers can capture value by offering qualified grades with established performance data rather than commodity materials alone. A supplier that provides formulation support, scale-up data, compaction profiles, and regulatory documentation has a stronger commercial position than one offering only standard lactose or microcrystalline cellulose.

What commercial opportunities exist for excipient suppliers and contract manufacturers?

High-priority opportunities

1. Lactose-free direct-compression platform
   Target: replacement of lactose monohydrate while preserving dissolution and tablet size.

2. Low-dose content-uniformity technology
   Target: 2 mg to 5 mg tablets, where segregation and assay variability are most sensitive.

3. Color-free starter-pack system
   Target: reduction of pigment use while maintaining clear dose identification.

4. Moisture-robust formulation and packaging
   Target: tropical markets and long distribution routes.

5. Integrated starter-pack manufacturing
   Target: calendar blisters, serialization, and automated dose-sequence inspection.

6. Authorized-generic formulation support
   Target: rapid launch after NCE exclusivity and patent barriers expire.

7. Regional private-label products
   Target: markets where excipient declarations, dietary restrictions, or procurement rules favor lactose-free or titanium-dioxide-free products.

Standalone excipient sales would likely be modest compared with the value of a complete formulation and packaging platform. The greatest opportunity lies in combining excipient supply with development services, analytical support, and commercial-scale packaging.

Key Takeaways

• PONVORY is an immediate-release ponesimod tablet with a conventional lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate core.
• The product’s 14-day dose-escalation regimen creates the main formulation and packaging challenge.
• Low-dose content uniformity, blend segregation, coating consistency, and starter-pack inspection are the highest-value technical targets.
• Lactose-free and moisture-robust formulations offer the clearest excipient opportunities.
• Color-free reformulation is possible but creates patient-identification and human-factors risks.
• Conventional excipient substitutions are unlikely to create strong standalone patent protection without an unexpected technical effect.
• PONVORY received FDA approval on March 18, 2021, with five-year NCE exclusivity generally extending through March 18, 2026.
• Generic competition, rather than biosimilar competition, is the relevant post-exclusivity risk.
• A commercially useful formulation patent should connect the excipient system to stability, dissolution, tablet-size reduction, or low-dose uniformity.
• A combined excipient, manufacturing, and starter-pack platform is more defensible than a routine tablet composition.

FAQs About PONVORY Excipients and Commercial Strategy

Does PONVORY contain lactose?

Yes. The U.S. PONVORY label identifies lactose monohydrate as an inactive ingredient in the tablet core.[1]

Can a generic PONVORY product use different excipients?

Yes. An ANDA applicant can generally use different inactive ingredients if the product meets FDA requirements for safety, quality, dissolution, and bioequivalence.

Is PONVORY a biologic eligible for biosimilar competition?

No. PONVORY contains the small-molecule drug ponesimod. Competition would proceed through the generic-drug pathway, not the biosimilar pathway.

Why is the PONVORY starter pack commercially important?

The starter pack contains multiple dose strengths used over a 14-day escalation schedule. It requires coordinated tablet manufacture, color or imprint differentiation, blister packaging, and sequence control.

What is the best excipient opportunity for a PONVORY competitor?

A lactose-free, moisture-robust, direct-compression formulation that maintains low-dose content uniformity and supports efficient starter-pack production offers the strongest combination of technical and commercial value.

References

1. U.S. Food and Drug Administration. (2023). PONVORY (ponesimod) tablets, prescribing information. Janssen Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2021, March 18). FDA approves new oral drug to treat relapsing forms of multiple sclerosis. U.S. Department of Health and Human Services.

4. International Council for Harmonisation. (2003). Q8(R2): Pharmaceutical development. ICH.

5. International Council for Harmonisation. (2009). Q6A: Specifications: Test procedures and acceptance criteria for new drug substances and new drug products. ICH.